BIO-key International Enters into $2.5 Million Warrant Inducement Transaction

BIO-key International (Nasdaq: BKYI) entered into a warrant inducement agreement with an existing institutional investor covering warrants issued on October 28, 2025.

Rhea-AI Summary

BIO-key International (Nasdaq: BKYI) entered into a warrant inducement agreement with an existing institutional investor covering warrants issued on October 28, 2025. The investor agreed to exercise warrants for 618,334 shares of common stock at a reduced exercise price of $4.06 per share, subject to beneficial ownership limits, generating expected gross proceeds of about $2.5 million before fees.

In consideration, BIO-key will issue the investor 1,236,668 new unregistered warrants with a $4.06 exercise price, exercisable for five years starting on stockholder approval under Nasdaq rules. BIO-key plans to file an SEC registration statement for resale of shares issuable upon exercise of the new warrants.

Positive

• Expected gross cash proceeds of approximately $2.5 million from warrant exercises
• Immediate issuance of 618,334 shares at $4.06 provides non-debt financing
• New warrants for 1,236,668 shares carry a defined five-year term after approval
• BIO-key plans SEC registration of resale shares, supporting future liquidity for the investor

Negative

• Exercise of existing warrants adds 618,334 new shares of common stock, causing dilution
• Potential future dilution from up to 1,236,668 additional shares upon new warrant exercise
• New warrants become exercisable only after stockholder approval under Nasdaq rules, adding execution uncertainty

News Explained

The agreement creates contingent dilution, while gross proceeds equal 628.5 days of first-quarter operating cash use before fees.

The release describes an agreement, with the New Warrants exercisable only after stockholder approval; if exercised, the additional shares would increase total share count and reduce existing holders’ percentage ownership.

The expected gross proceeds of $2.5 million, before fees and expenses, equal 628.5 days of operating cash use in the quarter ended March 31, 2026, at that quarter’s rate.

Sources and calculations

• BIO-key International warrant inducement transaction release (2026-08-11)
• Dilution definition
• BIO-key 2026 first-quarter fundamentals (2026Q1)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $2,500,000 / ($358,001 / 90) = 628.5 days

Argus Aug 11 session 12 alerts

-6.47% close to close 33.4x rel. volume Open Argus

Details

Market move: BKYI -6.47% in the Aug 11 session. warrant inducement transaction

-7.5% Trough in 51 min

$4.07M Market Cap

On Aug 11, the day this news came out, BKYI closed 6.47% below the previous close. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner recorded 12 alerts for this stock that day. Relative volume reached 33.4x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 11 session.

Market Context

On Aug 11, the day this news came out, the stock closed 6.5% below the previous close. The Central B...

Analysis

On Aug 11, the day this news came out, the stock closed 6.5% below the previous close. The Central Bank of Jordan selection was followed by a -10.53% 24-hour reaction. A sharp decline here would extend a historical pattern of negative responses to favorable operational announcements, despite the financing proceeds.

Key Figures

Gross proceeds: $2.5 million Existing warrant shares: 618,334 shares Reduced exercise price: $4.06 per share +3 more

Gross proceeds

$2.5 million

Warrant exercise transaction, before fees and expenses

Existing warrant shares

618,334 shares

Shares exercisable under outstanding warrants

Reduced exercise price

$4.06 per share

Exercise price for existing and new warrants

New warrant shares

1,236,668 shares

Unregistered warrants issued to the investor

New warrant term

Five years

Term beginning from stockholder approval

Warrants issued

October 28, 2025

Date of the outstanding warrants

Historical Context

5 past events · Latest: Aug 07

5 events

1. Aug 07

   Investor call notice

   24h Move

   +1.3%

   Q2 2026 investor call scheduled for August 14 at 10 a.m. ET

2. Aug 06

   Partnership announcement

   24h Move

   -1.5%

   Maktabi Tech partnership expanded identity security distribution across Saudi education

3. Jul 28

   Customer selection

   24h Move

   -10.5%

   Central Bank of Jordan selected BIO-key for national biometric authentication initiative

4. Jul 07

   Nasdaq compliance

   24h Move

   +43.4%

   Nasdaq compliance restored and trading resumed on the Capital Market

5. Jul 02

   Industry showcase

   24h Move

   -8.9%

   Biometric identity solutions showcased at Jordan banking cybersecurity workshop

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

warrant inducement agreement, beneficial ownership blocker provisions, placement agent, registration statement

4 terms

warrant inducement agreement financial

"entered into a warrant inducement agreement with an existing institutional investor"

A warrant inducement agreement is a contract in which a company offers warrants—rights to buy shares at a set price—to a person or group as a sweetener to secure their support, service, or approval for a transaction or role. Investors care because these warrants can increase the total number of shares if exercised, diluting existing ownership and potentially changing the company’s valuation and control dynamics; think of it as paying someone with future stock-buying tickets to get them on board.

beneficial ownership blocker provisions regulatory

"subject to compliance with beneficial ownership blocker provisions included in the Warrants"

Provisions in corporate charters, shareholder agreements, or regulatory policies that prevent any single person or group from acquiring more than a set percentage of a company’s voting or economic rights without triggering restrictions or forced actions. They matter to investors because they can block concentration of control, limit takeover attempts or large stake builds, and change how shares trade or how votes are cast—like a speed governor on a car that keeps one driver from going too fast.

placement agent financial

"Maxim Group LLC is acting as the exclusive Placement Agent"

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

registration statement regulatory

"agreed to file a registration statement with the Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLMDEL, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), a global innovator in Identity and Access Management (IAM) and biometric authentication solutions, today announced it has entered into a warrant inducement agreement with an existing institutional investor for the exercise of certain outstanding warrants that the Company issued on October 28, 2025 (the “Warrants”). Pursuant to the warrant inducement agreement, the investor has agreed to exercise the Warrants to purchase an aggregate of 618,334 shares of the Company's common stock at a reduced exercise price of $4.06 per share, subject to compliance with beneficial ownership blocker provisions included in the Warrants. The gross proceeds from the exercise of the Warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and estimated offering expenses.

Maxim Group LLC is acting as the exclusive Placement Agent for the transaction.

In consideration for the exercise of the Warrants, the Company also agreed to issue to the investor unregistered warrants to purchase an aggregate of 1,236,668 shares of the Company's common stock with an exercise price of $4.06 per share (the “New Warrants”). The New Warrants will be exercisable upon the receipt of stockholder approval of the exercise of the New Warrants in accordance with applicable Nasdaq rules and have a term of exercise equal to five years from the date of such stockholder approval. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon exercise of the New Warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About BIO-key International, Inc. (www.bio-key.com)
BIO-key International (NASDAQ: BKYI) is a global provider of Identity and Access Management (IAM) and biometric authentication solutions, protecting more than 40 million users worldwide. BIO-key’s PortalGuard platform delivers enterprise-grade Multi-Factor Authentication, Single Sign-On, passwordless authentication, biometric identity verification, and Identity-Bound Biometrics (IBB), helping organizations strengthen security while simplifying user access across cloud and on-premises environments.

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BIO-key undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the value of BIO-key International’s (BKYI) August 11, 2026 warrant inducement transaction?

The transaction is expected to generate approximately $2.5 million in gross proceeds. According to BIO-key, this comes from the investor’s agreed exercise of warrants for 618,334 shares at a reduced exercise price of $4.06 per share, before fees and expenses.

How many BIO-key (BKYI) shares are involved in the August 2026 warrant inducement agreement?

The investor will exercise warrants for 618,334 shares and receive new warrants for 1,236,668 shares. According to BIO-key, all shares relate to common stock at a $4.06 exercise price, subject to ownership blockers and future stockholder approval.

What is the exercise price and term of the new BIO-key (BKYI) warrants issued in August 2026?

The new warrants have a $4.06 per share exercise price and a five-year term. According to BIO-key, they become exercisable only after stockholders approve their exercise under applicable Nasdaq rules, starting the five-year exercise period from that approval date.

When will the new BIO-key (BKYI) warrants from the August 11, 2026 transaction become exercisable?

The new warrants become exercisable upon receipt of required stockholder approval. According to BIO-key, stockholder approval must comply with applicable Nasdaq rules, and the new warrants will then remain exercisable for five years from the date that approval is obtained.

How might the August 2026 warrant inducement affect BIO-key (BKYI) shareholder dilution?

The immediate exercise adds 618,334 shares, increasing the share count. According to BIO-key, the investor also receives new warrants for 1,236,668 shares, which, if later exercised, would further increase outstanding shares and contribute to additional dilution.

Will BIO-key (BKYI) register the shares underlying the new August 2026 warrants?

Yes, BIO-key has agreed to file a registration statement with the SEC for resale. According to BIO-key, this registration will cover the shares of common stock issuable upon exercise of the new warrants, facilitating potential future secondary market transactions.